Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata
“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema